Cytora Therapeutics

Cytora Therapeutics is a clinical-stage biotechnology company based in Israel that specializes in regenerative medicine and allogeneic stem cell therapies. The company has developed a proprietary platform technology to produce "off-the-shelf" therapeutic doses of human oral mucosal stem cells (hOMSCs), which possess unique regenerative potential. Its lead program, hOMSC200, has successfully completed a Phase 1/2a clinical trial for chronic diabetic foot ulcers, demonstrating significant wound closure and a favorable safety profile. Cytora is also expanding its pipeline into neurodegenerative diseases, with an ongoing Phase 1 study for Multiple System Atrophy and preclinical programs for Parkinson's and Alzheimer's diseases. In early 2026, the company established a major strategic partnership with Made Scientific and Zeo ScientifiX to manufacture and commercialize its therapies in the United States, initially targeting the Florida market under specialized stem cell access laws.